+
+
+

meet celularity

Celularity is a clinical-stage cell therapeutics company delivering transformative allogeneic cellular therapies, engineered from the postpartum human placenta, in cancer immunotherapy and functional regeneration. Some of our placenta-derived allogeneic cell therapy products aim to augment immunity by harnessing a patient’s own immune system to combat disease. Our other products seek to augment longevity by targeting organ and tissue repair and functional regeneration. With this approach, our ambition is to augment human immunity and longevity, and to improve the human health span.

Backed by 100+ years of combined experience, our seasoned team of biopharmaceutical executives, scientists and clinicians has been integral to the success of numerous programs across discovery research, clinical development and commercialization in cancer immunotherapies and cell therapeutics. Everyone at Celularity is passionate about developing innovative treatment options that will make a meaningful difference in patients’ lives.

our pipeline

cell therapy pipeline

LEADERSHIP TEAM

BOBHARIRI

ROBERT J. HARIRI, MD, PHD

FOUNDER & CEO

Celgene, Weill Cornell Medicine

xiaokui-zhang

XIAOKUI ZHANG, PHD

EVP, CHIEF SCIENTIFIC OFFICER

Celgene, Rockefeller University

nassirHabboubi

NASSIR HABBOUBI, MD

CHIEF MEDICAL OFFICER

Sanofi, Novartis

john-haines

JOHN R. HAINES

EVP, CHIEF ADMINISTRATIVE OFFICER

Andiscern, Ionetix, University of Pennsylvania

section-link

DAVID C. BEERS

CHIEF FINANCIAL OFFICER

Goldman Sachs, T. Rowe Price

beth-steinbrenner

BETH STEINBRENNER

EVP, HUMAN RESOURCES

Celgene, Nabisco, Kraft Foods

BOARD OF DIRECTORS

peter-diamandis

PETER DIAMANDIS, M.D.

VICE CHAIR

Founder & Executive Chairman, XPRIZE; Executive Founder, Singularity University

henri-ji

HENRI JI, Ph.D.

BOARD MEMBER

Co-Founder & CEO, Sorrento Therapeutics

andrew-pecora

ANDREW PECORA, M.D., F.A.C.P., C.P.E.

BOARD MEMBER

Chief Innovation Officer, John Thereur Cancer Center

jaisim-shah

JAISIM SHAH

BOARD MEMBER

Chief Executive Officer, Scilex Pharmaceuticals

john-sculley

JOHN SCULLEY

VICE CHAIR

Former CEO of Apple Inc; Former President of Pepsi-Cola

andrew-c-von-eschenbach

ANDREW C. VON ESCHENBACH, M.D.

BOARD MEMBER

Former Commissioner, United States FDA

LKT

KOK-THAY LIM

BOARD MEMBER

Chairman and Chief Executive Officer, Genting Berhad

robin-smith

ROBIN SMITH M.D., M.B.A.

BOARD MEMBER

Founder and Board Chair of Stem for Life Foundation; Founder and Board Chair of Cura Foundation

newsroom

Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cryopreserved NK Cell Therapy

January 22, 2020

Read More

Celularity Presents Pre-Clinical and Clinical Data from its Allogeneic, Placental-Derived, Off-the-Shelf Cell Therapy Platform at the 2019 ASH Annual Meeting

December 9, 2019

Read More

Celularity Presents Pre-Clinical Data Demonstrating the Potential of Allogeneic Placental-Derived, Cryopreserved NK Cell Therapy (CYNK-001) in Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting

November 22, 2019

Read More

Celularity to Present New Data at the ASH Annual Meeting on Novel Allogeneic, Off the Shelf, Placental Derived CAR T and NK Cell Therapy Programs

November 6, 2019

Read More

Celularity Enters Lease to Develop Advanced Cell Manufacturing and Research Facility for Commercial-Scale Placental-Derived Allogeneic Cell Therapies

April 11, 2019

Read More

Celularity Announces Results of Phase 1 Studies of PNK-007, an Allogeneic, Off-the-Shelf, Placental-Derived Cell Therapy, at AACR Annual Meeting 2019

March 29, 2019

Read More

First Clinical Results Evaluating Allogeneic, Off-The-Shelf, Placental-Derived Cells to be Presented by Celularity at 2019 AACR Annual Meeting

February 27, 2019

Read More

Celularity Acquires CariCord, Inc., Adds Important Biosourcing Assets, Strategic Relationship with the University of Colorado's ClinImmune Labs

August 31, 2018

Read More

Celularity Announces $250M in Funding to Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional Regeneration

February 15, 2018

Read More

join us

To view opportunities at celularity click here

contact us

Celularity, Inc.

33 Technology Drive

Warren, NJ 07059

For Investor Inquiries: john.haines@celularity.com

For Media Inquiries: media@celularity.com

Privacy Policy           |         Terms of Use